Director/PDMR Shareholding

May 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")

Notification of transactions by person discharging managerial responsibilities

1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a) Name Matt Walker
2. Reason for the notification
a) Position / status Head of Technical Operations - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")

 

 
Identification code ISIN: US82481R1068
b) Nature of the transaction Receipt of ADSs following the vesting of Restricted Stock Units ("RSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on May 2, 2016. In accordance with the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.

 

(Details of related disposal of ADSs are referenced in section 5. below.)
c) Price(s) and volume(s) Price(s) Volume(s)
$0 822
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e) Date of the transaction May 2, 2018
f) Place of the transaction N/A
5. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares ("ADSs")

 

 
Identification code ISIN: US82481R1068
b) Nature of the transaction Automated disposal of ADSs in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c) Price(s) and volume(s) Price(s) Volume(s)
$159.4427 322
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e) Date of the transaction May 2, 2018
f) Place of the transaction NASDAQ

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Christoph Brackmann christoph.brackmann@shire.com +41 795 432 359
Robert Coates rcoates@shire.com +44 203 549 0874
Sun Kim sun.kim@shire.com +1 617 588 8175
Media    
Katie Joyce kjoyce@shire.com  +1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey.

www.shire.com

Ads